研究单位：[1]BeiGene[2]Sichuan Cancer Hospital Chengdu,Sichuan,China,610042[3]General Hospital of Tianjin Medical University Tianjin,Tianjin,China,300070[4]Tianjin Medical University Cancer Institute and Hospital Tianjin,Tianjin,China[5]Yunnan Cancer Hospital Kunming,Yunnan,China[6]The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou,Zhejiang,China,310009[7]Zhejiang Cancer Hospital Hangzhou,Zhejiang,China,310022[8]The First Affiliated Hospital of College of Medicine,Zhejiang University Hangzhou,Zhejiang,China[9]Ningbo No.2 Hospital Ningbo,Zhejiang,China[10]Sun Yat-sen University - Cancer Center (SYSUCC) Guangzhou,China,510060
研究目的：
The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.
